What is the effect of statins on amputations, and survival in peripheral vascular disease?

indicación de tratamiento con estatinasThe prevalence of peripheral arterial disease is between 15% and 20% of patients older than 65 years and its severity is greatly underestimated. In fact, annual mortality is higher in patients with peripheral arterial disease (8.2%) than in those after acute myocardial infarction (6.3%). Despite the above, medical advice and efforts to modify risk factors are far below those observed in those with coronary heart disease or stroke.

Definitely we are doing something wrong…


Read also: Statin Pre-Treatment for the Prevention of Peri-Procedural Events in Carotid Artery Stenting.


The guidelines for the indication of statins in peripheral vascular disease, are largely extrapolated from the data of coronary disease or stroke. Therefore, the objective of this study was to determine the effect of the intensity of statin treatment in this specific population over hard end points such as amputation and mortality.

An intensive treatment with statins was compared with a moderate/mild treatment and antiplatelet therapy, but without statins.

A cohort of 155,647 patients with peripheral vascular disease was included, of which more than a quarter (28%) were not receiving statins.


Read also: When to Indicate Statin Therapy.


The use of intensive treatment was only 6.4%, compared to 18.4% of those with a diagnosis of coronary or carotid disease.

The incidence of amputation and death, decreased significantly with any dose of statins versus antiplatelet therapy alone. But this reduction was also increasing as the intensity of the treatment increased (intensive treatment amputation HR 0.67, CI 95% 0.61 to 0.74 versus mild/moderate treatment; amputation HR 0.81 0.75 to 0.86 and intensive treatment mortality HR 0.74, CI 95% 0.70 to 0.77 versus mild/moderate mortality HR 0.83 0.81 to 0.86 with p<0.001 for all comparisons).


Read also: Early Endarterectomy Seems Superior to Carotid Stenting in Symptomatic Patients.


The association between the intensity of statin treatment and the reduction of amputations and death, remained significant after adjustment with propensity score, sensitivity analysis and subgroup analysis.

Conclusion

Statins, particularly aggressive schemes, are underutilized in peripheral vascular disease. This is the first population study that shows that the intensity of statin treatment at the time of diagnosis of peripheral vascular disease is associated with a reduction in amputations and mortality.

Original title: Statins Have a Dose-Dependent Effect on Amputation and Survival in Peripheral Artery Disease Patients.Reference: Shipra Arya et al. Circulation. 2018 Jan 12. Epub ahead of print.

Reference: Shipra Arya et al. Circulation. 2018 Jan 12. Epub ahead of print.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

TCT 2024 | SIRONA: Randomized Study Comparing Sirolimus-Coated vs Paclitaxel-Coated Balloon Angioplasty in Femoropopliteal Disease

This prospective, randomized, multicenter, investigator-initiated non-inferiority study compared the use of sirolimus-coated balloon (MagicTouch) vs paclitaxel-coated balloon in endovascular treatment.  The primary objective was to...

TCT 2024 | PEERLESS: Mechanical Thrombectomy with FlowTriever vs Catheter-Directed Thrombolysis in Intermediate Risk PTE

Pulmonary embolism (PE) continues to be the third cause of cardiovascular mortality. The current clinical guidelines recommend anticoagulation in intermediate risk patients presenting right...

STEACS and the Use of Bivalirudin vs. Heparin: In Search of BRIGHT-4 Outcomes

Various studies and registries have previously shown the impact of post-percutaneous coronary intervention (PCI) complications on the survival of patients with ST-segment elevation acute...

TAVR and Atrial Fibrillation: What Anticoagulants Should We Use?

The prevalence of atrial fibrillation (AF) in TAVR patients ranges from 15 to 30%, depending on series. This arrhythmia has been associated to higher...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...